ADC Therapeutics SA Common Shares (ADCT)
Stock · NYSE · Health Care
$1.4as of 10/16/2026
Price chart
Active signals
ADCT Signal Track Record
How signals performed across all stocks →What ADCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -3.0% | 45% | October 8, 2026 |
| Bollinger Band Breakout | 21 | -8.3% | 43% | October 7, 2026 |
| Bollinger Band Breakdown | 20 | -1.5% | 45% | August 20, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -2.3% | 50% | April 27, 2026 |
| Any 20-session window (baseline) | -3.4% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or ref…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 188
- Website
- adctherapeutics.com/
Fundamentals
- 1-day range
- $1.4$1.51
- Market cap
- $143.73M
- P/E (trailing)
- —
- P/E (forward)
- -0.94
- EPS (trailing)
- $-0.73
- Dividend yield
- —
- Beta
- 1.86
- Avg. volume
- 1.54M
How ADC Therapeutics SA Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
ADC Therapeutics SA Common Shares Competitors
Chosen by industry and closest market cap.
- ADCTADC Therapeutics SA Common Shares$1.4▼ 6.04%Market cap $143.73MP/E —$0.7796$4.98
- CNTNCanton Strategic Holdings Inc. Common Stock$1.7▼ 9.36%Market cap $143.45MP/E —$1.75$6.89
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- MISTMilestone Pharmaceuticals Inc. Common Shares$0.707▼ 11.07%Market cap $146.91MP/E —$0.7075$3.06
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA Common Shares | $143.73M | — | $1.4 | ▼ 6.04% | $0.7796$4.98 |
| CNTN Canton Strategic Holdings Inc. Common Stock | $143.45M | — | $1.7 | ▼ 9.36% | $1.75$6.89 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| MIST Milestone Pharmaceuticals Inc. Common Shares | $146.91M | — | $0.707 | ▼ 11.07% | $0.7075$3.06 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC SaysYahoo · 10/9/2026
- ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull ThesisSeekingAlpha · 10/9/2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo · 10/8/2026
- ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendmentsbenzinga · 10/8/2026
- ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsYahoo · 10/8/2026
- ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty AmendmentsBenzinga · 10/8/2026
- ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - SlideshowSeekingAlpha · 9/12/2026
Insider Activity
Insider Actions →- Ameet Mallik · June 30, 2026 · Grant675.0K
- Jose Carmona · June 30, 2026 · Grant203.7K
- Mohamed Zaki · June 30, 2026 · Grant213.9K
- Peter J. Graham · June 30, 2026 · Grant221.1K
- Viviane Monges · June 3, 2026 · Tax Withholding2.6K @ $3.08
- Peter Hug · June 3, 2026 · Tax Withholding2.2K @ $3.08
- Robert Azelby · June 3, 2026 · Tax Withholding12.6K @ $3.08
- Jean-Pierre Bizzari · June 3, 2026 · Tax Withholding12.6K @ $3.08
- Victor Sandor · June 3, 2026 · Tax Withholding12.6K @ $3.08
- Ron Squarer · June 3, 2026 · Tax Withholding15.2K @ $3.08
- Timothy Coughlin · June 3, 2026 · Tax Withholding12.6K @ $3.08
- Viviane Monges · June 1, 2026 · Grant45.0K
- Peter Hug · June 1, 2026 · Grant45.0K
- Robert Azelby · June 1, 2026 · Grant45.0K
- Jean-Pierre Bizzari · June 1, 2026 · Grant45.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments
ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.